Compare MPX & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MPX | CADL |
|---|---|---|
| Founded | 1965 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 264.3M | 578.8M |
| IPO Year | 2000 | 2021 |
| Metric | MPX | CADL |
|---|---|---|
| Price | $8.15 | $8.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 53.4K | ★ 2.1M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | ★ 7.16% | N/A |
| EPS Growth | N/A | ★ 58.62 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $244,419,000.00 | $125,000.00 |
| Revenue This Year | $13.72 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.32 | N/A |
| 52 Week Low | $6.83 | $4.35 |
| 52 Week High | $10.08 | $9.27 |
| Indicator | MPX | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 54.89 | 58.29 |
| Support Level | $7.89 | $4.91 |
| Resistance Level | $8.76 | $9.27 |
| Average True Range (ATR) | 0.25 | 0.65 |
| MACD | 0.01 | -0.12 |
| Stochastic Oscillator | 36.72 | 30.53 |
Marine Products Corp is a manufacturer of fiberglass motorized boats distributed and marketed through its independent dealer network. The company's only operating segment is Powerboat Manufacturing Business. Its product offerings include Chaparral sterndrive, outboard pleasure boats, and Robalo outboard sport fishing boats. The company offers its products to the family recreational markets through its Chaparral brand and to the sportfishing market through its Robalo brand.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.